Navigation Links
InterMune Announces Issuance of U.S. Patent for ITMN-191
Date:2/19/2009

ormation available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Pegasys(R) and Copegus(R) are registered trademarks of Roche


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/2/2014)... The inventors of tinAway, a novel ... are seeking support for development costs through a crowdfunding ... http://igg.me/at/tinaway ), was launched on September 1, 2014. , ... and is based on ten years of neuroscience ... and software engineers, Dr. Ian Dixon and Mr. Tony ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... on,endocrinology and oncology, today reported financial and operating results,for the ... Highlights, - Advancement of cetrorelix Phase 3 program ... trial: patient enrollment completed; - ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
... LI-COR Biosciences continues to,expand its offering of ... new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye ... IgG, and IRDye 800CW Goat,Anti-Rat IgG antibodies ... detection for multiple applications including,quantitative Westerns, In-Cell ...
Cached Biology Technology:AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 7
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... fittest survive has been called into question by new research ... A collaboration between the Universities of Exeter and Bath in ... in the US, challenges our current understanding of evolution by ... The work represents a new approach to studying evolution that ...
... done by Mark Lusk and colleagues at the Colorado ... solar cells. Their latest work describes how the size ... energy to electrons to generate electricity. The results ... ACS Nano . The advance provides evidence ...
... NeoProteomics Inc., a biomarker development and software ... Case Western Reserve University. The deal has potential ... diabetes, and inflammatory diseases. Proteomics is the ... structures of biological systems. NeoProteomics, founded in 2006 ...
Cached Biology News:Research shows not only the fittest survive 2Size matters: Smaller particles could make solar panels more efficient 2Case Western Reserve and NeoProteomics announce exclusive option 2
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Biology Products: